Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
08:28am, Monday, 18'th Aug 2025
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR ) for viola
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
02:49am, Monday, 18'th Aug 2025
LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("C
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR
10:23am, Sunday, 17'th Aug 2025
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Saturday, 16'th Aug 2025
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors a
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLAS
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acquire
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class Action Lawsuit and an Upcoming Deadline
04:37pm, Thursday, 14'th Aug 2025
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed a
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders
08:45am, Thursday, 14'th Aug 2025
NEW YORK , Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
05:40pm, Wednesday, 13'th Aug 2025
NEW YORK , Aug. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR).
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR
10:23am, Wednesday, 13'th Aug 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such inve
